EURACi005-A

iPSC Line

Provider

External iPSC Databases

General iPSC Information

• Zanon A et al. Generation of an induced pluripotent stem cell line (EURACi005-A) from a Parkinson's disease patient carrying a homozygous exon 3 deletion in the PRKNgene. Stem cell research. 2019 Dec;41:101624.
• Casamassa A et al. A Link between Genetic Disorders and Cellular Impairment, Using Human Induced Pluripotent Stem Cells to Reveal the Functional Consequences of Copy Number Variations in the Central Nervous System-A Close Look at Chromosome 15. International journal of molecular sciences. 2020 Mar 9;21(5).
• Castelo Rueda MP et al. Generation and characterization of induced pluripotent stem cell (iPSC) lines of two asymptomatic individuals carrying a heterozygous exon 7 deletion in Parkin (PRKN) and two non-carriers from the same family. Stem cell research. 2022 Apr;60:102692.
• Gilmozzi V et al. Generation of an induced pluripotent stem cell line (EURACi014-A) from a Parkinson's disease patient with an A53T mutation in the SNCA gene by an integration-free reprogramming method. Stem cell research. 2022 Apr;60:102713.
• Castelo Rueda MP et al. Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers. NPJ Parkinson's disease. 2023 Apr 18;9(1):65.
• Zanon A et al. Intracellular delivery of Parkin-RING0-based fragments corrects Parkin-induced mitochondrial dysfunction through interaction with SLP-2. Journal of translational medicine. 2024 Jan 16;22(1):59.

General